$CLNN

Clene (CLNN) plans to submit an NDA for its ALS drug in Q4, following FDA-requested biomarker analyses. The company reported consistent neurofilament reductions across trials and believes its data links biomarker changes to clinical benefits. Clene aims for an FDA decision by year-end and a potential commercialization decision by early 2027.

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_967804.htm EXHIBIT 99.1 ex_967804.htm Exhibit 99.1 CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene expects to submit a New Drug Application for CNM-Au8 ® in ALS under the accelerated approval pathway in early fourth quarter

Chidozie Ugwumba has reported a 9.7% beneficial ownership stake in Clene Inc. (CLNN), totaling 1,351,071 shares. This includes both issued common stock and shares issuable upon the exercise of immediately exercisable Tranche A, Tranche B, and Common Stock Purchase Warrants. The filing is an amendment to a Schedule 13G and references 12,778,307 shares outstanding as of May 14, 2026, as per Clene Inc.'s Form 10-Q.

SymBiosis II LLC, an entity associated with major Clene (NASDAQ: CLNN) shareholder Ugwumba Chidozie, reported selling a total of 78,679 shares of Clene Inc. common stock in two open-market transactions. These sales occurred on May 1, 2026, for 5,795 shares at $6.01, and on May 4, 2026, for 72,884 shares at $6.80. Following these transactions, SymBiosis II LLC indirectly holds 198,890 shares of Clene Inc.

A 10% owner of Clene (NASDAQ: CLNN), through the associated entity SymBiosis II, LLC, sold 19,497 shares of common stock in open-market transactions over three days in late April 2026. The sales were executed at prices ranging from $5.63 to $6.08 per share. Following these transactions, SymBiosis II, LLC still indirectly holds 277,569 shares of Clene Common Stock.

A Form 144 filing indicates that Symbiosis II LLC has reported multiple proposed and executed sales of Common Stock in Clene Inc. (NASDAQ: CLNN) during January–March 2026. The filing details numerous open-market dispositions, including 31,297 shares sold on March 31, 2026, for $152,316.52 and 32,705 shares sold on January 12, 2026, for $179,867.17, with individual trade sizes and cash amounts provided for each transaction. This filing provides transparency into Symbiosis II LLC's recent trading activities in CLNN shares.

Clene Inc. (CLNN) has secured an $8 million subaward for the third year of its $45.1 million NIH grant, supporting an Expanded Access Program for CNM-Au8 in amyotrophic lateral sclerosis (ALS). This agreement with New York University covers the period from September 1, 2025, to August 31, 2026, with reimbursements against invoices. Clene maintains full control over its background intellectual property, granting no licenses to NYU or the U.S. government, while ensuring confidentiality for proprietary data.

Ugwumba Chidozie, a ten percent owner of Clene Inc. (NASDAQ:CLNN), sold 32,474 shares of common stock for approximately $161,519 in three transactions between January 16 and January 21, 2026. These sales, conducted indirectly through Symbiosis II, LLC, leave Chidozie's entity still owning 617,824 shares. The company has also secured over $28 million in funding and received an FDA Type C meeting for its ALS drug candidate CNM-Au8, with Benchmark reiterating a Buy rating.

Chidozie Ugwumba, a major shareholder in Clene Inc. (NASDAQ:CLNN), sold 7,030 shares of the company's stock on December 16th, which was part of a larger series of trades between December 4th and 18th, totaling approximately 201,218 shares. Following these transactions, Ugwumba holds 401,850 shares valued at about $2.54 million. The insider selling coincided with a 7.4% drop in CLNN shares to $6.04, amidst mixed analyst ratings and the company reporting a quarterly EPS loss.

Chidozie Ugwumba, a major shareholder in Clene Inc. (NASDAQ:CLNN), sold 56,577 shares on December 3rd at an average price of $7.86, totaling approximately $444,695. This initial sale, detailed in an SEC filing, reduced his stake to 594,368 shares. He continued selling throughout December, offloading roughly 185,047 shares in total, including this initial transaction.